Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference
Karen Mulder, Shahid Ahmed(Emory University), Duc Le(University of Saskatchewan), Janine M. Davies(Australian Wildlife Conservancy), Bryan Brunet(University of Saskatchewan), Duc Le(University of Saskatchewan), John Paul McGhie(BC Cancer Agency), Christina Kim, Deepti Ravi(Saskatchewan Health Authority), Howard J. Lim(BC Cancer Agency), Adnan Zaidi(University of Saskatchewan), Dorie-Anna Dueck(University of Saskatchewan), P Hebbard(CancerCare Manitoba), Devin Schellenberg(BC Cancer Agency), Daniel J. Renouf(BC Cancer Agency), Vallerie Gordon(CancerCare Manitoba), Corinne Doll(Alberta Health), Ralph P. W. Wong(CancerCare Manitoba), Jason Park(CancerCare Manitoba), Shahida Ahmed(CancerCare Manitoba)
Cited by 1
Related Papers
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|436
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
HER2-directed therapy: current treatment options for HER2-positive breast cancer
|Breast Cancer|2015|183
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
|Cancers|2021|183